Letter on “Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease (
                    MASLD
                    )”

Di Chang; Yimeng Zhou

doi:10.1111/apt.70555

journal article Feb 16, 2026

Letter on “Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )”

Di Chang

Yimeng Zhou

Alimentary Pharmacology & Therapeutics Vol. 63 No. 8 pp. 1179-1180 · Wiley

View at Publisher Save 10.1111/apt.70555

Topics

No keywords indexed for this article. Browse by subject →

References

10

[1]

10.1111/apt.70433

[2]

10.1002/hep.32774

[3]

10.1111/apt.70409

[4]

10.1007/s11892-025-01603-4

[5]

10.1111/jgh.16480

[6]

10.4093/dmj.2025.0007

[7]

10.3389/fendo.2025.1605484

[8]

10.1111/apt.70360

[9]

10.1111/apt.70382

[10]

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )

Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili et al.

Alimentary Pharmacology & Therapeutics 10.1111/apt.70516

Cited By

1

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply

Kaleb Tesfai, Luis Antonio Diaz · 2026

Alimentary Pharmacology & Thera...

Metrics

1

Citations

10

References

Details

Published: Feb 16, 2026
Vol/Issue: 63(8)
Pages: 1179-1180
License: View

Authors

D

Di Chang

Department of Critical Care Medicine Shengjing Hospital of China Medical University Shenyang China

Y

Yimeng Zhou

Department of Infectious Diseases Shengjing Hospital of China Medical University Shenyang China

Cite This Article

Di Chang, Yimeng Zhou (2026). Letter on “Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )”. Alimentary Pharmacology & Therapeutics, 63(8), 1179-1180. https://doi.org/10.1111/apt.70555

Letter on “Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )”

You May Also Like